Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb randomized double-blind placebo-controlled study of HSK31679 in Chinese patients with nonalcoholic steatohepatitis
CTR20233629Phase 2Completed
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HSK31679 in metabolic dysfunction-associated steatohepatitis (MASH), sponsored by Haisco Pharmaceutical Group Co., Ltd.. Started Jan 2024; status: completed.
02
Drugs
HSK31679
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on CTR20233629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233629.